The Latest Personalized Medicine Industry Statistics Explained
The global personalized medicine market size is expected to reach USD 3.18 trillion by 2025.
The statistic indicates that the global personalized medicine market is predicted to grow significantly, with an anticipated market size of USD 3.18 trillion by 2025. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, such as their genetic makeup or lifestyle. The expected growth in this market size suggests a growing emphasis on precision medicine and the use of advanced technologies for healthcare delivery. This substantial increase in market value highlights the increasing importance and adoption of personalized medicine approaches in the healthcare industry, potentially leading to improved patient outcomes and more efficient healthcare practices.
The specialty drugs segment accounted for more than 42.0% revenue share in 2018.
The statistic that the specialty drugs segment accounted for more than 42.0% revenue share in 2018 indicates that a significant portion of the overall revenue generated in the pharmaceutical industry during that year came from specialty drugs. Specialty drugs are high-cost medications that are often used to treat complex and chronic conditions, such as rare diseases or certain types of cancer. The fact that this segment contributed over 42.0% of the total revenue highlights the growing importance of specialty drugs in the healthcare market and underscores the significant economic impact of these specialized medications on the pharmaceutical sector in 2018.
In 2018 North America led the personalized medicine market in terms of revenue.
The statistic that in 2018 North America led the personalized medicine market in terms of revenue indicates that North America, including the United States and Canada, generated the highest revenue from personalized medicine compared to other regions across the globe during that specific year. This suggests that the personalized medicine market in North America was the most financially lucrative and potentially had the highest level of investment, research, and development activities in personalized medicine technologies and treatments during that time period. This statistic highlights the significance of North America as a key player in advancing personalized medicine and shaping its future growth and impact on healthcare outcomes.
The therapeutic segment of the personalized medicine market is projected to grow at a CAGR of 10.6% by 2025.
This statistic indicates that the therapeutic segment of the personalized medicine market is expected to experience a compound annual growth rate (CAGR) of 10.6% by 2025. This suggests that there will be a significant increase in the market size and demand for personalized medicine specifically focused on therapeutic applications. The projected growth rate of 10.6% signifies a strong and steady upward trend in the adoption and utilization of personalized medicine approaches within the healthcare industry, likely driven by advancements in technology, genomic research, and innovations in pharmaceuticals. As such, this forecast highlights the growing importance and relevance of personalized medicine in providing targeted treatment options tailored to individual patients, ultimately leading to improved healthcare outcomes and patient care.
Genomics and proteomics technologies accounted for a significant share of the global market in 2018.
The statement indicates that in 2018, genomics and proteomics technologies made up a substantial portion of the global market. Genomics focuses on studying an organism’s complete set of DNA, while proteomics involves analyzing the entire complement of proteins present in a biological sample. The significant share of the market suggests that these technologies were in high demand and were likely contributing significantly to advancements in fields such as personalized medicine, agriculture, and biotechnology. This underscores the importance of genomics and proteomics in driving innovation and research across various industries, making them key players in the global market landscape.
Europe is expected to register the fastest CAGR of nearly 12.0% from 2019 to 2025.
This statistic indicates that Europe is projected to experience the fastest Compound Annual Growth Rate (CAGR) of close to 12.0% over the period from 2019 to 2025. A high CAGR suggests rapid growth in a particular market or industry, in this case likely referring to economic or business-related activities in Europe. This implies a significant expansion and development of sectors within the European economy during the specified time frame. Such growth can have various implications, such as increased job opportunities, enhanced investments, and overall prosperity within the region. It highlights Europe as a promising market for potential investors and businesses looking to capitalize on this anticipated growth trajectory.
The genomics segment of personalized medicine industry is expected to reach USD 746.9 million by 2023.
The statistic indicates that the genomics segment within the personalized medicine industry is projected to grow significantly, with an expected value of USD 746.9 million by the year 2023. This suggests a substantial increase in the utilization and demand for genomics-based approaches in personalized medicine over the next few years. Genomics plays a crucial role in tailoring medical treatment and interventions to individual patients based on their genetic makeup, allowing for more targeted and effective healthcare strategies. The substantial growth forecasted for the genomics segment highlights the importance and potential impact of personalized medicine in the healthcare industry, with increasing emphasis on precision and personalized approaches to patient care.
Personalized Medical Care in the U.S. has a Market Size of $532.3bn in 2021.
The statistic “Personalized Medical Care in the U.S. has a Market Size of $532.3bn in 2021” indicates the total value of the market for customized healthcare services in the United States in the year 2021. This market size represents the aggregate amount of money spent on personalized medical care services, which cater to individuals’ specific needs based on factors such as genetics, lifestyle, and health history. The substantial market size of $532.3 billion highlights the growing demand and investment in personalized healthcare solutions, reflecting a shift towards more tailored and efficient medical treatments and services tailored to meet patients’ unique requirements.
Cancer dominates the therapeutic area for personalized medicine with a market share of 30% in 2018.
This statistic indicates that cancer is the predominant focus area within personalized medicine, claiming a significant market share of 30% in 2018. Personalized medicine, also known as precision medicine, involves tailoring medical treatment to the individual characteristics of each patient, such as genetic makeup or specific biomarkers. The fact that cancer holds such a substantial market share suggests that a considerable amount of research, investment, and development efforts within personalized medicine are directed towards addressing various types of cancer. This underscores the importance of personalized approaches in cancer treatment, potentially leading to more effective and targeted therapies for cancer patients.
Diagnostics segment captured the largest revenue share in 2018.
The statement ‘Diagnostics segment captured the largest revenue share in 2018’ indicates that among all the segments considered, the Diagnostics segment contributed the most to the total revenue generated in the year 2018. This suggests that the Diagnostics segment was the most profitable or largest revenue-generating sector within the industry during that specific time period. It could imply that there was high demand for diagnostic products or services in 2018, leading to greater revenue generation compared to other segments. This statistic is important for understanding the financial performance and market dynamics of different segments within the industry.
Personalized medical care has an expected Growth Rate of 2.3% in 2021.
The statistic “Personalized medical care has an expected Growth Rate of 2.3% in 2021” indicates the anticipated rate at which the personalized medical care industry is projected to expand over the course of the year 2021. This growth rate of 2.3% suggests that there is a positive trend towards increased adoption and utilization of personalized healthcare services among individuals and healthcare providers. This statistic may reflect various factors such as advancements in medical technology, increasing demand for personalized treatment plans, and a shift towards more patient-centric healthcare delivery models. The 2.3% growth rate provides insight into the potential trajectory of the personalized medical care sector and highlights its importance in shaping the future of healthcare.
The genomics in personalized medicine market was valued at USD 7.27 billion in 2020.
The statistic indicates that the genomics in personalized medicine market generated revenues of USD 7.27 billion in 2020. This figure represents the total value of products and services related to the use of genomics in personalized medicine within that specific year. Genomics in personalized medicine refers to the application of genetic information to tailor medical treatments and interventions to individual patients, aiming to improve outcomes and minimize adverse effects. The market value reflects the demand for personalized healthcare solutions based on genetic data and is a key indicator of the growth and investment in this evolving field of healthcare.
Personalized Medicine is expected to represent almost 80% of the entire pharmaceutical market by 2026.
The statistic stating that Personalized Medicine is expected to represent almost 80% of the entire pharmaceutical market by 2026 indicates a significant shift towards more targeted and individualized healthcare approaches. Personalized Medicine involves tailoring medical treatments and interventions based on an individual’s unique genetic makeup, lifestyle, and environment. The increasing advancements in technologies such as genomics, data analytics, and artificial intelligence are driving this trend by enabling healthcare providers to better understand and predict how patients will respond to different treatments. This statistic suggests a future where healthcare will be more precise, effective, and potentially more cost-efficient as treatments are customized to each person’s specific needs and characteristics.
The pharmacogenomics segment was valued at USD 5,385.1 million in 2020.
The statistic states that the pharmacogenomics segment, which refers to the study of how an individual’s genetic makeup influences their response to drugs, was estimated to have a market value of USD 5,385.1 million in the year 2020. This indicates the significant financial worth and growth potential of the pharmacogenomics industry, reflecting the increasing interest and investment in personalized medicine and targeted drug therapies based on genetic information. The value suggests a substantial market size and underscores the importance of leveraging genetic data to optimize treatment outcomes and improve patient care in the healthcare sector.
The personalized medicine market in Asia-Pacific region is estimated to grow at a CAGR of 11.72% between 2018 and 2023.
The statistic indicates that the personalized medicine market in the Asia-Pacific region is projected to experience significant growth at a Compound Annual Growth Rate (CAGR) of 11.72% between 2018 and 2023. This implies that the market for personalized medicine, which tailors medical treatments to individual characteristics such as genetics, is expected to expand rapidly over the specified timeframe. Such growth may result from factors such as advancements in technology, increasing investment in healthcare research and development, and a growing awareness and demand for personalized medical treatments among the population in the Asia-Pacific region. This statistic suggests promising opportunities for stakeholders in the industry and underscores the increasing importance and adoption of personalized medicine approaches in the healthcare sector within the region.
The application of pharmacogenomics in Oncology accounted for 32.8% revenue share in 2018 within the market.
This statistic indicates that in 2018, the portion of total revenue generated in the market of pharmaceuticals and genomics coming specifically from the field of oncology and the application of pharmacogenomics was 32.8%. Pharmacogenomics involves studying how an individual’s genetic makeup influences their response to drugs, particularly in the field of cancer treatment. This high revenue share suggests that the integration of pharmacogenomics in oncology has been financially significant, likely indicating a growing trend towards personalized medicine and targeted therapies within the oncology market. This statistic highlights the importance and potential impact of pharmacogenomics in improving treatment effectiveness and optimizing patient outcomes in cancer care.
Personalized Medicine Therapeutics is expected to grow at a CAGR of 7.1% from 2021 to 2028.
This statistic indicates that the market for Personalized Medicine Therapeutics is projected to experience a Compound Annual Growth Rate (CAGR) of 7.1% over the period from 2021 to 2028. This means that, on average, the market is expected to increase its value by 7.1% each year during this timeframe. The positive CAGR suggests that there is a growing demand and adoption of personalized medicine therapeutics, likely driven by advancements in healthcare technology, increased awareness of personalized treatment options, and a shift towards more tailored and precise medical interventions. This growth trend indicates a promising outlook for the personalized medicine industry over the next several years.
In 2021, there were more than 400 marketed targeted therapies, which continues to grow.
The statistic “In 2021, there were more than 400 marketed targeted therapies, which continues to grow” indicates a significant advancement in the field of personalized medicine and targeted treatments. Targeted therapies are medications that specifically target molecules involved in the growth and spread of cancer cells, offering patients more effective and less toxic treatment options. The fact that there are over 400 marketed targeted therapies highlights the rapid expansion of this area of medicine and the increasing focus on precision and individualized treatments. This trend suggests a promising future for patients with various types of cancer and other diseases, as research and development efforts continue to yield novel targeted therapies for improved clinical outcomes.
Investment in the personalized medicine sector reached $ personalized investment in 2020.
The statistic “Investment in the personalized medicine sector reached $ personalized investment in 2020” indicates the total sum of money that was invested in businesses, research, and technologies within the personalized medicine sector in the year 2020. Personalized medicine involves tailoring medical treatment and healthcare practices to individual characteristics such as genetic makeup, lifestyle, and environment. The mentioned investment amount suggests a significant financial commitment and interest in advancing this area of healthcare to develop more precise and effective treatments, diagnostics, and preventive measures based on personalized factors for improved patient outcomes and healthcare delivery.
References
0. – https://www.www.marketsandmarkets.com
1. – https://www.www.ibisworld.com
2. – https://www.www.biotecnika.org
3. – https://www.www.bioplanassociates.com
4. – https://www.www.pharmiweb.com
5. – https://www.www.grandviewresearch.com
6. – https://www.www.researchandmarkets.com
7. – https://www.www.mordorintelligence.com
